China Clinical Trials Outsourcing Congress

The pressure has never been so great to conduct successful global clinical trials on time and on budget and the pharmaceutical industry has continued to explore emerging markets in an effort to deliver sustained growth and reduce costs.

The role of China as a key player for conducting preclinical and clinical trials has strengthened as the regulatory authorities have sought to soften the regulatory climate and also due an ever growing labour pool available to support clinical trials.

China’s changing population is beginning to provide increased consumer demand as large numbers of Chinese seek to become more westernised. As the population ages and lifestyles change we are seeing a subsequent increase in western diseases such as diabetes and cardiovascular issues amongst others creating an increased demand for drugs to treat these diseases.

Inevitably China’s huge population provides for faster patient recruitment and the large percentage of patients without health insurance motivates high participation and patient retention.

The 2^nd China Clinical Trials Outsourcing Congress will focus on how to meet the challenges of conducting clinical and preclinical studies in China and assessing the challenges and advantages of partnering with regional CROs against setting up operations in China. Other issues such as regulatory procedures, patient recruitment and retention, logistics and data management will also be reviewed through case studies and keynote presentations from industry experts all actively involved in conducting preclinical and clinical studies in China.